Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Selects Cyntellect s Technology for RNAi Studies

Note: This article has been updated to reflect a factual inaccuracy at the end of the original story, which stated that Cyntellect was a subsidiary of Oncosis.


NEW YORK, Nov. 4 (GenomeWeb News) - Eli Lilly has selected Cyntellect's LEAP technology for high-throughput RNA interference studies, Cyntellect said today.


LEAP, or Laser Enabled Analysis and Processing technology, involves a CCD camera imaging system with mirrors that steer the image in tandem with the cameras, and a laser that then works with the imaging system, according to Cyntellect, of San Diego.


Cyntellect has earlier said it believes this laser-driven method, which it terms optoinjection, is better than other techniques for transfecting RNAi or siRNA into cells because it more efficiently transfects cells than other methods, kills fewer cells, and allows users to transfect one cell but not the adjacent one with the RNA molecules.


The parties did not disclose the financial terms of the agreement.


Cyntellect, a spin-out of moribund stem cell cancer treatment company Oncosis, announced in July that it had received an $183,000 SBIR grant to develop its LEAP platform.

The Scan

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, demonstrating that distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.